Alcon to acquire ESBATech for up to $589 million
This article was originally published in Scrip
Executive Summary
Alcon is to buy ESBATech, a private Swiss biotechnology company focused on antibody fragments, for up to $589 million.
You may also be interested in...
Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab
Novartis says nAMD eye treatment brolucizumab showed further advantages over Eylea in two Phase III studies, reinforcing plans to file in late 2018 for a commercial launch in 2019.
Innovation not M&A to drive Bayer growth in LatAm
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
2010 Scrip 100 - Is Anvisa a friend of innovators?
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.